Syndax Moves Closer to Pivotal Trials of Selective Lung Cancer Treatment

Xconomy Boston — 

Executives from Syndax Pharmaceuticals are spending their post-holiday week in Amsterdam, where they’ll be presenting three sets of data on the company’s lung cancer drug at the International Association for the Study of Lung Cancer conference. The drug, called entinostat, is in Phase 2 clinical testing, the results of which will be critical to advancing Syndax’s plan to move into Phase 3 next year.

Syndax, based in Waltham, MA, is one of several Boston-area companies pursuing drugs designed around epigenetics—the molecular changes in cells that can activate or de-activate genes without affecting the underlying DNA. Entinostat is a selective histone deacetylase inhibitor. It acts against certain enzymes that influence specific epigenetic alterations that drive cancer growth and drug tolerance. Syndax’s strategy is to test the drug in combination with other cancer therapies, so as to boost the receptiveness of a patient’s tumor to drugs to which it might not normally respond.

In previous studies, Syndax showed that in non-small cell lung cancer patients with high levels of a specific protein called e-cadherin, entinostat plus the blockbuster drug erlotinib (Tarceva) produced a survival benefit over entinostat plus placebo. The e-cadherin biomarker is found in about 40 percent of patients with the disease. On July 6 in Amsterdam, researchers for the company will present data further defining the e-cadherin biomarker and showing that some patients with resistance to erlotinib benefitted from the addition of Syndax’s drug.

Syndax CEO Joanna Horobin says the further definition of the e-cadherin biomarker, as described in the data being presented, will allow the company to better design an effective Phase 3 program. “The most important thing is that this gives us a robust way to select patients” who are most likely to benefit from entinostat, she says. “We can identify the right patients to treat and monitor them while they’re being treated.”

Horobin says the company aims to start a Phase 3 study of entinostat plus erlotinib in the first half of next year. She adds that if the study succeeds, the drug will most likely be able to be marketed with a companion diagnostic to identify patients whose tumors have high levels of e-cadherin.

As the field of epigenetics continues to evolve, the cancer community is starting to explore the potential of combination epigenetic approaches. Towards that end, Syndax and the National Cancer Institute are studying entinostat … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

Comments are closed.